Nicox Announces Participation in Various Sector Events in the First Half of the Year
The ophthalmic laboratory Nicox will participate in several scientific and financial congresses between January and June 2026. The company will notably present clinical data on its drug candidate NCX 470 at the American Glaucoma Society congress in February, according to the press release.
Investor and Financial Professional Engagements
According to the group, Nicox will be present at four events dedicated to investors and finance professionals in the coming months. The company will participate in the Allinvest Securities Biomed Forum on January 29 in Paris, followed by the MidCap Event on February 5 in Frankfurt. The company also plans to attend the Investor Access conference on April 8 and 9 in Paris, as well as the BIO International Convention from June 22 to 25 in San Diego. Members of the management will be available for individual interviews during these events, the statement indicates.
Presentations at the American Glaucoma Society Annual Congress
According to Nicox, several presentations on the Denali and Whistler studies will be made at the 2026 annual congress of the American Glaucoma Society, which will be held from February 19 to 22 in Rancho Mirage, California. This data concerns NCX 470, a bimatoprost nitric oxide donor eye drop designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. According to the group, this drug candidate has been licensed to Ocumension Therapeutics for the Chinese, Korean, and Southeast Asian markets, and to Kowa for the rest of the world. The company will also be present at the annual congress of the Association for Research in Vision and Ophthalmology from May 3 to 7 in Denver.
Ophthalmology Solutions and Preclinical Research
Nicox indicates that it is developing ophthalmology solutions aimed at maintaining vision and improving eye health. The group also mentions conducting a preclinical research program, NCX 1728, in collaboration with Glaukos. The company generates revenue from two marketed products: VYZULTA, licensed to Bausch + Lomb and marketed in the United States and 15 other territories for the treatment of glaucoma, and ZERVIATE, dedicated to allergic conjunctivitis and licensed notably to Harrow for the United States and to Ocumension Therapeutics for China and several Southeast Asian countries. Based in Sophia Antipolis, the company is listed on Euronext Growth Paris under the code ALCOX and is part of the CAC Healthcare index, the press release specifies.
